CD8 is a cell surface glycoprotein found on most cytotoxic T lymphocytes that mediates efficient cell-cell interactions within the immune system. CD8 acts as a co-receptor, and the T-cell receptor on the T lymphocyte recognizes antigen displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. The functional CD8 is either a homodimer composed of two alpha chains, or a heterodimer composed of one alpha and one beta chain. Both alpha and beta chains share significant homology to immunoglobulin variable light chains. CD8 identifies cytotoxic/suppressor t-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of t-cell mediated killing. CD8 alpha chains binds to class-I MHC molecules alpha-3 domains.
Mouse anti-human CD8 is conjugated to FITC and purified over an ion exchange column. Protein concentration is 1 mg/ml in PBS (after reconstitution).
Reported to be effective for flow cytometry and is also weakly cytotoxic.
To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols
Advanced Targeting Solutions(ATS)是一家位于圣地亚哥的生物技术公司,致力于为科学研究和药物开发提供高质量的靶向试剂。ATS被称为“萨波林人”,最初致力于为神经科学研究界提供研究工具。多年来,这些工具已用于科学研究和药物开发的所有领域。公司目前的产品线包括针对性毒素,抗体和定制服务,旨在帮助科学家研究系统功能,细胞功能,疾病和病症。ATS率先将靶向结合物用于“分子手术”技术。这些产品包括针对胆碱能性前脑神经元,去甲肾上腺素能和肾上腺素能神经元,巨噬细胞和小胶质细胞的特定损伤剂,以及能侵袭所有神经元上表达的抗原决定簇的泛神经元剂。此外,ATS还出售“次级结合物”,使用户可以将自己的靶向剂转化为特定的细胞毒性工具,并筛选抗体进行内在化。ATS已商业化,并提供了由Douglas Lappi博士开发和完善的Saporin技术平台的访问权限。拉皮博士与医学博士Ronald Wiley合作。在他们的学术实验室中,以验证使用主要的皂素结合物192-IgG-SAP来建立阿尔茨海默氏病模型。丹妮丝·希金斯(Denise Higgins)将她的业务专长和国际销售/营销经验带到了团队中,并将继续致力于将这一创新技术带给全球科学家。